TAG’s Magic Mountains of Debt: Sovereign Debt Crises as Critical Barriers to Ending TB and Investing in Sustainable Development Goals analyzes the impact of sovereign debt in depressing investments in TB programs, services, and R&D in high-TB burden nations.
TAG, APCASO, and Diagnostics Equity Consortium (DEC) hosted a two-part webinar series exploring the evolving TB diagnostic landscape and strategies to increase TB testing coverage, with a specific focus on the South-East Asia and Western-Pacific regions.
TAG is one of the endorsers of this Diagnostic Equity Consortium statement and call to action advocating for scaling up access to diagnostics to address the deadly gaps in TB testing.
Survey now extended until April 24! TAG, with support from Wellcome, is conducting a scoping exercise of community partners and interventions to support new TB vaccine readiness.
Learn more about the latest TB vaccine research here: TAG’s TB Vaccines Pipeline Report Learn more about the Global TB CAB here: 10-Year TB CAB Anniversary Evaluation Report and Podcast Learn more about TAG’s work on pre-approval access…
This policy brief describes the crucial role NIH plays in supporting research on new products to prevent, diagnose, and cure TB. This research is especially important at a time when new forms of drug resistance are emerging globally, and rates of TB are rising in the U.S. With continued and increased funding, NIH can protect Americans from the growing threat of TB at home and abroad.
The new 2025 update of An Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis lays out what community advocates need to know about WHO-recommended regimens for drug-resistant TB.
To accompany the updated Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis, TAG also developed three additional educational materials to support community-based and civil society organizations leading treatment literacy, peer support, and community-led monitoring activities:
TAG is pleased to share the latest edition of our Tuberculosis Vaccines Pipeline Report, written by TB project co-director Mike Frick. The report provides the latest information on 17 vaccine candidates under clinical development and summarizes ongoing, planned, and recently completed clinical trials in two comprehensive tables.
Treatment Action Group (TAG) opposes in the strongest possible terms the termination of National Institutes of Health (NIH) research awards and contracts to South Africa, feared following reporting by Science.